IXICO plc announced that it has been contracted by a top five CRO on behalf of a new pharma client to provide its imaging biomarker services for a Phase 3 clinical trial for patients with a type of Parkinsonian disorder. The trial is due to run for just under 5 years and is worth in excess of £1 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.125 GBX | 0.00% | -1.72% | -43.00% |
06-19 | Ixico Bags Over GBP1 Million Contract for Parkinsonian Disorder Study | MT |
06-19 | AIM WINNERS & LOSERS: Ixico and Light Science Technologies win deal | AN |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-43.00% | 4.35M | |
+22.13% | 46.93B | |
+37.63% | 39.08B | |
-8.42% | 38.48B | |
+29.71% | 31.01B | |
-13.75% | 26.14B | |
+10.92% | 25.88B | |
+36.18% | 12.53B | |
-6.58% | 11.36B | |
-12.28% | 10.65B |
- Stock Market
- Equities
- IXI Stock
- News IXICO plc
- IXICO plc Announces New Pharma Client Contract Valued in Excess of £1 Million for A Study of A Parkinsonian Disorder